Biotechnology - Anti-virals, Mergers & Acquisitions

Filter

Popular Filters

Biozone Pharma plans reverse merger with Cocrystal Discovery

03-12-2013

USA-based Biozone Pharmaceuticals shares dropped nearly 5.5% when it revealed last week it had agreed…

Anti-viralsBiotechnologyBiozone PharmaceuticalsCocrystal DiscoveryMergers & Acquisitions

Vivaldi Biosciences acquires clinical stage influenza vaccine assets

13-10-2013

Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

FDA approves Protein Sciences egg-free flu vaccine Flublok; and Octapharma's Octaplas

18-01-2013

The US Food and Drug Administration revealed it has approved privately-held US biotech firm Protein Sciences…

Anti-viralsBiotechnologyFlublokMergers & AcquisitionsNorth AmericaOctapharmaOctaplasPanblokPharmaceuticalProtein Sciences CorpRegulationVaccines

Australia's Benitec to acquire US RNAi firm Tacere

15-10-2012

Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire…

Anti-viralsBenitec BiopharmaBiotechnologyMergers & AcquisitionsPharmaceuticalTacere Therapeutics

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes

02-10-2012

On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Synergy Pharma gains rights to shingles drug from Bristol-Myers

28-08-2012

US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

RusNano to start production of vaccines and organogels

09-01-2012

Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset

22-11-2011

In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Back to top